Clinical TrialMay 7, 2026, 04:21 PM
CytomX Reports Positive Varseta-M Phase 1 CRC Data
AI Summary
CytomX Therapeutics announced positive data from its Phase 1 dose expansion study of varsetatug masetecan (Varseta-M) in patients with advanced colorectal cancer. The company completed enrollment for Varseta-M Dose Optimization and expects further data in 2H 2026 to guide a potential registrational trial. Financially, CytomX reported $346.7 million in cash, cash equivalents, and investments as of March 31, 2026, extending its cash runway to at least the second half of 2028, following a $250 million equity offering. Total revenue for Q1 2026 was $10.3 million, with a net loss of $18.2 million.
Key Highlights
- Positive Phase 1 data for Varseta-M in advanced colorectal cancer announced March 16, 2026.
- Varseta-M Dose Optimization enrollment completed with 40 patients as of April 2026.
- Additional Varseta-M Phase 1 data expected 2H 2026 to inform registrational trial design.
- Cash, cash equivalents, and investments totaled $346.7 million as of March 31, 2026.
- Cash runway extended to at least the second half of 2028.
- Total revenue was $10.3 million for Q1 2026, down from $50.9 million in Q1 2025.
- Net loss attributable to common stockholders was $18.2 million for Q1 2026.
- CX-801 Phase 1 study in advanced melanoma is ongoing, with initial combination data expected by end of 2026.